PRECIOUS Study recruiting in the US
Our Mission:
To improve outcomes for patients by guiding treatment choices
Our Vision:
Providing the tools that guide precision medicine in inflammatory disease
Incidence of inflammatory disease is rising globally
Diseases linked to genetics and environment
Unpredictable disease course has prevented optimum treatment
Our technology predicts patient disease course, informing treatment decisions
PredictSURE® IBD test available for inflammatory bowel disease
Pipeline of tests in development
helping to deliver
The right treatment, to the right patient, at the right time.
PredictImmune is a global biotechnology company. Our technology is the result of over 15 years’ research at the University of Cambridge and guides personalised treatment of patients with immune-mediated diseases.
We are developing tools to enable better disease management and an improved quality of life for patients with chronic diseases including inflammatory bowel disease (IBD) and multiple sclerosis (MS). Our first product – PredictSURE® IBD – a prognostic test for both Crohn’s disease (CD) and ulcerative colitis (UC) is now available.
Our test
Award-winning PredictSURE IBD is the world’s first validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease (Crohn’s disease and ulcerative colitis).
PredictSURE IBD is based upon 15 years of extensive research on gene expression profiling of CD8+ T-cells. This simple blood-based biomarker test is a major step towards precision medicine in IBD.
Stratifies adult patients by risk of frequently relapsing disease
Based on a whole blood gene expression signature
Early testing aids optimal treatment choice
Latest news, blog & events
News
PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE® IBD
PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE® IBDCambridge, UK, 02 February: PredictImmune,...
Blog
The PRECIOUS Study – an update on PredictImmune’s observational study to demonstrate effectiveness of PredictSURE IBD in IBD patients in North America
In our most recent blog, we provide an update on the progress of the PRECIOUS study, discuss overcoming the challenges of recruiting to the study over the last few years and invite you to get involved and support the completion of the study…
Events
PredictImmune presenting at the Crohn’s & Colitis Congress® 2023
PredictImmune presenting at the Crohn’s & Colitis Congress® 2023Cambridge, UK, 16th January 2023 PredictImmune are pleased to announce that they...
Paul Lyons – VP Platform Delivery
Eoin McKinney – CSO
Andy Sandham, Chairman
